Xiao-Ming Zhang1, Qing-Li Dou1, Yingchun Zeng2, Yunzhi Yang3, Andy S K Cheng4, Wen-Wu Zhang5. 1. Department of Emergency, The Affiliated Baoan Hospital of Southern Medical University, The People's Hospital of Baoan ShenZhen, Shenzhen, Guangdong, People's Republic of China. 2. Department of Nursing, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. 3. Department of Nursing, The Affiliated Baoan Hospital of Southern Medical University, The People's Hospital of Baoan ShenZhen, Shenzhen, China. 4. Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hong Kong, Hong Kong, China. andy.cheng@polyu.edu.hk. 5. Department of Emergency, The Affiliated Baoan Hospital of Southern Medical University, The People's Hospital of Baoan ShenZhen, Shenzhen, Guangdong, People's Republic of China. xlnzxm1793@163.com.
Abstract
BACKGROUND: Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death in women worldwide. Recently, studies have been published with inconsistent findings regarding whether sarcopenia is a risk factor for mortality in breast cancer patients. Therefore, the aim of this systematic review and meta-analysis was to systematically assess and quantify sarcopenia as a risk factor for mortality in breast cancer patients. METHODS: In a systematic literature review of PubMed, EMBASE, and the Cochrane CENTRAL Library, we searched for observational studies written in English (from database inception until April 30, 2019) that reported an association between sarcopenia and breast cancer in women who were 18 years or older. RESULTS: A total of six studies (5497 participants) were included in this meta-analysis. Breast cancer patients with sarcopenia were associated with a significantly higher risk of mortality, compared to breast cancer patients without sarcopenia (pooled HR-hazard ratio = 1.71, 95% CI: 1.25-2.33, I2 = 59.1%). In addition, the results of age subgroup analysis showed that participants younger than 55 years with sarcopenia had a lower risk of mortality than participants aged 55 years and older with sarcopenia (pooled HR = 1.46, 95% CI: 1.24-1.72 versus pooled HR = 1.99, 95% CI: 1.05-3.78), whereas both have an increased risk of mortality compared to non-sarcopenic patients. Subgroup analyses regarding stage at diagnosis revealed an increased risk of mortality in non-metastatic patients compared to participants without sarcopenia (pooled HR = 1.91, 95% CI: 1.32-2.78), whereas the association was not significant in metastatic breast cancer patients. Other subgroup analyses were performed using different follow-up periods (> 5 years versus ≤5 years) and the results were different (pooled HR = 1.81, 95% CI: 1.23-2.65 versus pooled HR = 1.70, 95% CI: 0.80-3.62). CONCLUSIONS: The present study found that sarcopenia is a risk factor for mortality among female early breast cancer patients. It is imperative that more research into specific interventions aimed at treating sarcopenia be conducted in the near future in order to provide evidence which could lead to decreased mortality rates in breast cancer patients.
BACKGROUND:Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death in women worldwide. Recently, studies have been published with inconsistent findings regarding whether sarcopenia is a risk factor for mortality in breast cancerpatients. Therefore, the aim of this systematic review and meta-analysis was to systematically assess and quantify sarcopenia as a risk factor for mortality in breast cancerpatients. METHODS: In a systematic literature review of PubMed, EMBASE, and the Cochrane CENTRAL Library, we searched for observational studies written in English (from database inception until April 30, 2019) that reported an association between sarcopenia and breast cancer in women who were 18 years or older. RESULTS: A total of six studies (5497 participants) were included in this meta-analysis. Breast cancerpatients with sarcopenia were associated with a significantly higher risk of mortality, compared to breast cancerpatients without sarcopenia (pooled HR-hazard ratio = 1.71, 95% CI: 1.25-2.33, I2 = 59.1%). In addition, the results of age subgroup analysis showed that participants younger than 55 years with sarcopenia had a lower risk of mortality than participants aged 55 years and older with sarcopenia (pooled HR = 1.46, 95% CI: 1.24-1.72 versus pooled HR = 1.99, 95% CI: 1.05-3.78), whereas both have an increased risk of mortality compared to non-sarcopenicpatients. Subgroup analyses regarding stage at diagnosis revealed an increased risk of mortality in non-metastatic patients compared to participants without sarcopenia (pooled HR = 1.91, 95% CI: 1.32-2.78), whereas the association was not significant in metastatic breast cancerpatients. Other subgroup analyses were performed using different follow-up periods (> 5 years versus ≤5 years) and the results were different (pooled HR = 1.81, 95% CI: 1.23-2.65 versus pooled HR = 1.70, 95% CI: 0.80-3.62). CONCLUSIONS: The present study found that sarcopenia is a risk factor for mortality among female early breast cancerpatients. It is imperative that more research into specific interventions aimed at treating sarcopenia be conducted in the near future in order to provide evidence which could lead to decreased mortality rates in breast cancerpatients.
Entities:
Keywords:
Breast cancer; Mortality rate; Sarcopenia; Systematic review and meta-analysis
Authors: Guilherme Defante Telles; Miguel Soares Conceição; Felipe Cassaro Vechin; Cleiton Augusto Libardi; Marcelo Alves da Silva Mori; Sophie Derchain; Carlos Ugrinowitsch Journal: Front Physiol Date: 2022-06-16 Impact factor: 4.755
Authors: Mayra Tardelli de Jesus Testa; Paola Sanches Cella; Poliana Camila Marinello; Fernando Tadeu Trevisan Frajacomo; Camila de Souza Padilha; Patricia Chimin Perandini; Felipe Arruda Moura; José Alberto Duarte; Rubens Cecchini; Flavia Alessandra Guarnier; Rafael Deminice Journal: Front Oncol Date: 2022-07-01 Impact factor: 5.738
Authors: Ye Won Jeon; Hyung Soon Park; Yousun Ko; Yu Sub Sung; Byoung Yong Shim; Young Jin Suh; Hyun A Kim Journal: Breast Cancer Res Treat Date: 2021-07-20 Impact factor: 4.872
Authors: Calvin L Cole; John F Bachman; Jian Ye; Joseph Murphy; Scott A Gerber; Christopher A Beck; Brendan F Boyce; Gowrishankar Muthukrishnan; Joe V Chakkalakal; Edward M Schwarz; David Linehan Journal: J Cachexia Sarcopenia Muscle Date: 2021-05-07 Impact factor: 12.910